Lung cancer remains the leading cause of cancer death worldwide. The treatment of lung cancer depends on the patient's histopathological type, stage, molecular typing, and assessment of the patient's physical condition. Among the common subtypes of lung cancer, non-small cell lung cancer accounts for 85%. With the improved understanding of the genetic alterations that cause NSCLC, many new drugs for targeted therapy have been developed. In order to further accelerate the understanding of non-small cell lung cancer and the development of targeted drugs, we provide an in vivo transcriptional system for non-small cell lung cancer for the exploration of its molecular mechanism.

Target Genes Delivered In Vivo in Non-small Cell Lung Cancer

In the clinical research of Non-small cell lung cancer, targeted therapy drugs have become one of the research hotspots in oncology in recent years. A comprehensive gene mutation spectrum analysis was performed on tumor tissue. Among all mutation types, the most common mutation type was single nucleotide variate (SNV), followed by insertions/deletions (INDEL), fusion gene and copy number variation (CNV). Among these mutations, the most frequently mutated genes were EGFR, TP53, ERBB2, CDKN2A, and KRAS. These are the well-known NSCLC driver genes that have been reported. Other frequently mutated genes included MET, PTEN and ROS1, BRAF, NARS and CDK4. Most mutations were found in EGFR, ERBB2 and TP53. The most common gene rearrangements are ALK, RET and ROS1.

Figure 1. Lung cancer immune activation mode. (Leader AM, et al.; 2021)

In addition to the above genes, there are interesting non-small cell lung cancer-related genes that need to be explored and studied. Therefore, there is a need for an in vivo transfection system that can precisely target non-small cell lung cancer tissue and be taken up by tumor cells to function in vivo. The system can help researchers overcome various challenges encountered during in vivo transfection:

• Relevant molecular function studies can only be carried out in vitro, lacking important in vivo data
• Using in vitro transfection system for in vivo transfection, the transfection efficiency is very low;
• The in vivo transfection system used is not specific to non-small cell lung cancer tissues and cells, and is toxic to the body;
• The in vivo transfection system used cannot penetrate the non-small cell lung cancer tissue into the tumor tissue;
• The nucleic acid load of the in vivo transfection system is low, and it is difficult to achieve the expected effect;
• Etc…

Our Advantage:

• We can provide an in vivo transfection system for non-small cell lung cancer tissues and cells to achieve efficient transfection
• Our system can target multiple targets at the same time, improving targeting accuracy
• The in vivo transfection system has low toxicity to the body and is safe to use
• In vivo transfection system vectors can protect nucleic acids from degradation during in vivo delivery
• Persistent knockout effect in experimental animals after a single injection
• The system load is high, and the transfection needs of different doses can be completed
• Professional design and service team to provide you with reliable service and technical support
• Timely feedback of technical reports

CD BioSciences specializes in developing transfection systems and customizing transfection reagents for gene transfection using our core technologies. With our high-quality products and services, your transfection results can be greatly improved. If you can't find a perfect in vivo transfection system, you can contact us. We can provide one-to-one personal customization service.

References

1. Chen X, et al.; Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua. Mol Genet Genomic Med. 2020, 8(9):e1398.
2. Leader AM, et al.; Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell. 2021, 39(12):1594-1609.e12.

* For research use only. Not for use in clinical diagnosis or treatment of humans or animals.